Hepatic Encephalopathy - Pipeline Review, H2 2018

  • ID: 4590336
  • Drug Pipelines
  • 72 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AlfaSigma SpA
  • Cosmo Pharmaceuticals NV
  • Gilead Sciences Inc
  • MallInckrodt Plc
  • Spherium Biomed SL
  • Synlogic Inc
  • MORE
Hepatic Encephalopathy - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

Report Highlights:

This latest pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 5, 2, 2 and 1 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AlfaSigma SpA
  • Cosmo Pharmaceuticals NV
  • Gilead Sciences Inc
  • MallInckrodt Plc
  • Spherium Biomed SL
  • Synlogic Inc
  • MORE
Introduction

Report Coverage

Hepatic Encephalopathy - Overview

Hepatic Encephalopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hepatic Encephalopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatic Encephalopathy - Companies Involved in Therapeutics Development

AlfaSigma SpA

Cosmo Pharmaceuticals NV

Ferring International Center SA

Gilead Sciences Inc

MallInckrodt Plc

Spherium Biomed SL

Synlogic Inc

Umecrine Cognition AB

Hepatic Encephalopathy - Drug Profiles

GR-3027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLS-13019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBX-2660 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifamycin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifaximin SSD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selonsertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYNB-1020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THDP-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatic Encephalopathy - Dormant Projects

Hepatic Encephalopathy - Product Development Milestones

Featured News & Press Releases

Oct 20, 2017: Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting

Aug 23, 2017: Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting

Jun 01, 2017: Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis

May 26, 2017: Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease

Mar 08, 2017: Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy

Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy

Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis

Dec 07, 2016: Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy

Nov 10, 2016: Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia

Nov 02, 2016: Ocera Therapeutics: Update on OCR-

Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy

Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)

Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology

Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hepatic Encephalopathy, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hepatic Encephalopathy - Pipeline by AlfaSigma SpA, H2 2018

Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Hepatic Encephalopathy - Pipeline by Ferring International Center SA, H2 2018

Hepatic Encephalopathy - Pipeline by Gilead Sciences Inc, H2 2018

Hepatic Encephalopathy - Pipeline by MallInckrodt Plc, H2 2018

Hepatic Encephalopathy - Pipeline by Spherium Biomed SL, H2 2018

Hepatic Encephalopathy - Pipeline by Synlogic Inc, H2 2018

Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H2 2018

Hepatic Encephalopathy - Dormant Projects, H2 2018

List of Figures

Number of Products under Development for Hepatic Encephalopathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AlfaSigma SpA
  • Cosmo Pharmaceuticals NV
  • Ferring International Center SA
  • Gilead Sciences Inc
  • MallInckrodt Plc
  • Spherium Biomed SL
  • Synlogic Inc
  • Umecrine Cognition AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll